Top Markets
#1 Derive Derive +24.03%
#2 EXOD EXOD +22.08%
#3 SSV Network SSV Network +20.83%
#4 Velvet Velvet +20.04%
#5 The Black Bull The Black Bull +19.95%
#6 GALA GALA +18.96%
#7 XPIN Network XPIN Network +18.09%
#8 wojak wojak +17.61%
#9 Arowana Arowana +17.36%
#10 Ethena Staked ENA Ethena Staked ENA +17.01%
Coin of the day
Derive Derive
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Sirnaomics Ltd. Sirnaomics Ltd.

Sirnaomics Ltd.

2257
Classificação em ações #25049
Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in... Sirnaomics Ltd. is an RNA therapeutics biopharmaceutical company, founded in 2007 and headquartered in Gaithersburg, Maryland. The company is dedicated to identifying and developing innovative therapeutic compounds aimed at addressing significant medical needs across the United States and the People's Republic of China. Its leading pipeline assets include STP705, which is being investigated for conditions such as cutaneous squamous cell carcinoma in situ, basal cell carcinoma, various liver-related cancers (cholangiocarcinoma, hepatocellular carcinoma, liver metastases), as well as for keloid scar remodeling, hypertrophic scarring, and fat sculpting. Another prominent candidate, STP707, is designed to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, metastatic cutaneous squamous cell carcinoma, non-small cell lung cancer, and both liver and lung fibrosis. Beyond these lead programs, Sirnaomics is advancing STP355 for a range of cancers; STP369 for head and neck/bladder cancers; STP779 for liver, lung, and pancreatic cancers; and STP902 for breast cancer. The company's portfolio also extends to infectious diseases with STP702 for influenza, STP908 for COVID-19, the RIM730 COVID-19 vaccine, and STP909 for HPV/cervical cancer. Furthermore, its developmental pipeline encompasses STP122G for thrombotic disorders, STP125G for hypertriglyceridemia, STP144G for complement-mediated ailments, STP133G for cardiometabolic conditions, and STP155G for hepatitis B virus.
Preço da ação
$0.49443488
Valor de mercado
$53.84M
Variação (1 dia)
-0.90%
Variação (1 ano)
-60.89%
País
US
Negociar Sirnaomics Ltd. (2257)

Categoria

Healthcare
EPS de Sirnaomics Ltd. (2257)
EPS em 2026 TTM: 0
De acordo com os últimos relatórios financeiros e o preço das ações da Sirnaomics Ltd., o EPS atual da empresa (TTM) é 0. No final de 2026, a empresa teve um EPS de 0, igual a ao EPS de 2026, que foi de 0.
Histórico de EPS da Sirnaomics Ltd. de 2026 até 2026
EPS no final de cada ano
Ano EPS Alterar
Não há dados suficientes para as datas fornecidas.
EPS de empresas semelhantes ou concorrentes
Empresa EPS Diferença de EPS País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $2.98 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US